Human ALCAM/CD166 Antibody Summary
Trp28-Ala526
Accession # AAB59499
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human ALCAM/CD166 by Western Blot ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ALCAM/CD166 by Western Blot ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ALCAM/CD166 by Western Blot ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
View Larger
Detection of Human ALCAM/CD166 by Western Blot ST6GAL1 targeting decreases levels of a subset of N-glycoproteins that are known BTIC regulators.(A) Schematic of proteomic analysis of D456 BTICs with and without ST6GAL1 KD (n = 4 for each group of shNT, sh32, and sh33). IB with samples independent of the proteomic analysis verified that successful targeting ST6GAL1 resulted in decreased (B) PDGFRB, (C) ALCAM, and (D) NRP1 protein. (E) Schematic of pulldown using SNA-bound Agarose beads. (F) SNA pulldown and protein A/G bound agarose beads as a control demonstrated that PDGFRB, ALCAM, and NRP1 were targets for alpha 2,6 sialylation. (G) SNA pulldown of D456 PDX cells with ST6GAL1 KD compared with NT, illustrating differential pulldown of PDGFRB. (H) PDGF-BB–induced (10 minutes) activation of PDGFRB in D456 GBM PDX cells with ST6GAL1 KD compared with NT; IB for p-PDGFRB and total PDGFRB. The experiments were repeated in at least 3 independent biological replicates. Data from 1 representative experiment are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36345944), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: ALCAM/CD166
ALCAM, activated leukocyte cell adhesion molecule, is a type I membrane glycoprotein and a member of the immunoglobulin supergene family. It is also known as CD166, MEMD, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat. ALCAM is expressed on thymic epithelial cells, activated B and T cells, and monocytes. ALCAM can bind itself homotypically and is also capable of binding CD6, NgCAM, and other, as of yet, unidentified brain proteins. The ALCAM/CD6 interaction may be involved in T cell development and T cell regulation. Additionally, ALCAM/CD6 and ALCAM/NgCAM interactions may play roles in the nervous system. ALCAM has also been observed to be upregulated on highly metastasizing melanoma cell lines and may play a role in tumor migration. ALCAM is a 583 amino acid (aa) protein consisting of a 27 aa signal peptide, a 500 aa extracellular domain, a 24 aa transmembrane domain and a 32 aa cytoplasmic domain. The extracellular domain of ALCAM contains 5 Ig-like domains.
- Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
- Aruffo, A. et al. (1997) Immunol. Today 18:498.
- Degen, W.G. et al. (1998) Am. J. Pathol. 152:805.
Product Datasheets
Citations for Human ALCAM/CD166 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
5
Citations: Showing 1 - 5
Filter your results:
Filter by:
-
alpha2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth
Authors: S Gc, K Tuy, L Rickenback, R Jones, A Chakrabort, CR Miller, EA Beierle, VS Hanumanthu, AN Tran, JA Mobley, SL Bellis, AB Hjelmeland
JCI Insight, 2022-11-08;7(21):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Floor-plate-derived netrin-1 is dispensable for commissural axon guidance
Authors: C Dominici, JA Moreno-Bra, SR Puiggros, Q Rappeneau, N Rama, P Vieugue, A Bernet, P Mehlen, A Chédotal
Nature, 2017-04-26;0(0):.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC -
Expression of the immunoglobulin superfamily cell adhesion molecules in the developing spinal cord and dorsal root ganglion.
Authors: Gu, Zirong, Imai, Fumiyasu, Kim, In Jung, Fujita, Hiroko, Katayama, Kei ichi, Mori, Kensaku, Yoshihara, Yoshihir, Yoshida, Yutaka
PLoS ONE, 2015-03-31;10(3):e0121550.
Applications: ICC -
ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells.
Authors: Jannie KM, Stipp CS, Weiner JA
PLoS ONE, 2012-06-26;7(6):e39330.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma.
Authors: van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ, van Kempen LC
Oral Oncol., 2010-04-03;46(5):393-8.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-Fr
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human ALCAM/CD166 Antibody
There are currently no reviews for this product. Be the first to review Human ALCAM/CD166 Antibody and earn rewards!
Have you used Human ALCAM/CD166 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
